Single-dose nevirapine (sdNVP) reduces mother-to-child HIV transmission, but induces NVP resistance and subsequent NVP-based combination antiretroviral therapy (cART) may fail. Some resistance mutations affect NVP more than efavirenz (EFV). We evaluated virological suppression of EFV-based cART in women after sdNVP. A retrospective analysis matched 107 women who had received sdNVP within the 24 months before cART (cases) with women who had never received sdNVP (controls). By total cohort (intention-to-continue treatment) at week 96, 65% of cases and 73% of controls had a viral load (VL) <400 copies/mL and 63% of cases and 64% of controls had VL <25 copies/mL. At weeks 48 and 96, women starting cART less than six months after sdNVP (n = 20) had VL <400 copies/mL of 90% and 75%, respectively compared with 90% and 70%, respectively, for controls. Overall 172 (80%) women reached week 96. EFV-based cART, in field conditions, was effective for women after sdNVP, even within six months of sdNVP.
JacksonJB, MusokeP, FlemingT, Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomized trial. Lancet2003;362:859–68
2.
Department of Health. 2004. National Antiretroviral Treatment Guidelines. 1st edn. Pretoria, South Africa: Jacana, 2004
3.
JourdainG, Ngo-giang-HuongN, Le CoeurS, Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Eng J Med2004;351:229–40
4.
EshlemanSH, HooverDR, ChenS, Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis2005;192:30–6
5.
LockmanS, ShapiroRL, SmeatonLM, Response to antiviral therapy after a single, peripartum dose of nevirapine. New Eng J Med2007;356:135–47
6.
ChiBH, SinkalaM, StringerEM, Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS2007;21:957–64
MillerV, de BethuneMP, KoberA. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor Loviride. Antimocrob Agents Chemother1998;42:3123–9
9.
CasadoJL, MorenaA, HertogsK, Extent and importance of cross-resistance to efavirenz after nevirapine failure. AIDS Res Hum Retroviruses2002;18:771–5
10.
BachelerL, JeffreyS, HannaG. Genotypic resistance to efavirenz isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol2001;75:4999–5008
11.
KuhnL, SemrauK, RamachandranS, Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia. J Acquir Immune Defic Syndr2009;52:132–6
12.
StringerJSA, McConnellMS, KiarieJ, Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study. PLoS Med2010;7:e1000233
13.
CoovadiaA, MaraisB, AbramsE, Virological Response to NNRTI Treatment among Women who took Single-dose Nevirapine 18–36 Months Earlier. Presented at 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006
14.
CoffiePA, EkoueviDK, ChaixML, Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003–2006. Clin Infect Dis2008;46:611–21
15.
DlaminiH, PauA, FollmannD, No effect of Prior Nevirapine Use on 6-month Virologic and CD4 Responses after Commencement of Efavirenz-based Combination ART in a Cohort of South African HIV + Females. Presented at 16th Conference on Retroviruses and Opportunistic Infections, Montreal, 2009
16.
CheesemanSH, HattoxSE, McLaughlinMM, Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother1993;37:178–82
17.
EshlemanSH, JacksonJB. Nevirapine resistance after single-dose prophylaxis. AIDS Rev2002;4:59–63
18.
MartinsonN, MorrisL, GrayG, HIV Resistance and Transmission Following Single-dose Nevirapine in a PMTCT Cohort. Presented at 11th Conference on Retroviruses and Opportunistic Infections, San Franscico, 2004
19.
JohnsonJA, LiJF, MorrisL, Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis2005;192:16–23
20.
PalmerS, BoltzV, MartinsonN, Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci2006;103:7094–99
21.
ChaixML, EkoueviDK, RouetF, Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J Infect Dis2006;193:482–7
22.
FlysT, NissleyD, ClaasenC, Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis2005;192:24–9
23.
Wind-RitoloM, DurandC, CranmerL, Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. J Infect Dis2009;199:1301–9
24.
FlysTS, DonnellD, MwathaA, Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis2007;195:711–5
25.
EshlemanSH, MracnaM, GuayLA, Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission. (HIVNET 012) AIDS2001;15:1951–7
26.
CoovadiaA, HuntG, AbramsEJ, Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis2009;48:462–72
27.
HeneineW. When do minority drug-resistant HIV-1 variants have a major clinical impact. J Infect Dis2010;201:647–9
28.
NightingaleSL. From the FDA. JAMA1998;280:1472
29.
SaitohA, HullD, FranklinP, Myelomeningocele in an infant with intrauterine exposure to efavirenz. J Perinatol2005;25:555–6
30.
WattsDH, CovingtonDL, BeckermanK, Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy. Am J Obstet Gynecol2004;193:985–92
31.
BeraE, McCauslandK, NonkweloR, Birth defects following exposure to efavirenz-based antiretroviral therapy during pregnancy: a study at a regional South African hospital. AIDS2010;24:283–9
32.
TownsendCL, WilleyBA, Cortina-BorjaM, Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990–2007. AIDS2009;23:519–524
